IFG Advisory LLC Purchases 13,760 Shares of Johnson & Johnson $JNJ

IFG Advisory LLC raised its position in Johnson & Johnson (NYSE:JNJ) by 54.7% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 38,902 shares of the company’s stock after acquiring an additional 13,760 shares during the period. IFG Advisory LLC’s holdings in Johnson & Johnson were worth $7,213,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the company. Brighton Jones LLC grew its holdings in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after acquiring an additional 6,332 shares in the last quarter. United Bank boosted its position in Johnson & Johnson by 110.7% during the first quarter. United Bank now owns 9,279 shares of the company’s stock valued at $1,539,000 after purchasing an additional 4,876 shares during the last quarter. Sivia Capital Partners LLC grew its stake in Johnson & Johnson by 13.4% in the second quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock valued at $896,000 after purchasing an additional 692 shares in the last quarter. Wealth Group Ltd. increased its position in shares of Johnson & Johnson by 12.8% during the 2nd quarter. Wealth Group Ltd. now owns 1,482 shares of the company’s stock worth $226,000 after purchasing an additional 168 shares during the last quarter. Finally, Schnieders Capital Management LLC. increased its position in shares of Johnson & Johnson by 9.8% during the 2nd quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company’s stock worth $11,255,000 after purchasing an additional 6,584 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ opened at $245.28 on Thursday. The company’s 50-day moving average is $227.06 and its 200-day moving average is $203.31. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77. The firm has a market capitalization of $591.10 billion, a PE ratio of 22.20, a PEG ratio of 2.44 and a beta of 0.34. Johnson & Johnson has a fifty-two week low of $141.50 and a fifty-two week high of $251.71.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Saturday, January 31st. The company reported $2.46 EPS for the quarter. The business had revenue of $24.28 billion during the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. Equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 47.06%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 1,322 shares of the stock in a transaction on Friday, February 20th. The stock was sold at an average price of $245.66, for a total transaction of $324,762.52. Following the transaction, the executive vice president owned 25,447 shares in the company, valued at $6,251,310.02. This trade represents a 4.94% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the sale, the executive vice president directly owned 23,003 shares of the company’s stock, valued at $5,598,700.17. This represents a 21.22% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 30,142 shares of company stock valued at $7,360,528 over the last 90 days. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA Fast Track for nipocalimab in systemic lupus erythematosus — The drug earned Fast Track designation supported by positive Phase 2 data and an ongoing Phase 3 study, which can accelerate review timelines and boosts the pharma pipeline narrative. Nipocalimab Fast Track PR
• Positive Sentiment: New direct-to-consumer drug sales channel — J&J launched a U.S. website to sell certain medications directly to uninsured or out-of-pocket patients, which may expand access and create a new revenue stream outside traditional pharmacy channels. Reuters: Direct-to-consumer site
• Neutral Sentiment: Oncology and other late-stage programs showing progress — Early pasritamig data and other oncology moves underpin higher long-term estimates, but timelines and commercial execution remain key variables. Yahoo: Pipeline & legal update
• Neutral Sentiment: Investor access and upcoming results — J&J scheduled its first-quarter results call for April 14; the call and Q1 metrics will be the next catalysts for guidance and near-term sentiment. Earnings call notice
• Neutral Sentiment: Dividend and income investor interest — J&J continues to be highlighted among top dividend/dividend-growth picks, supporting demand from income-focused investors even amid broader volatility. Dividend aristocrat piece
• Neutral Sentiment: Analyst stance: Hold with limited upside — Bank of America reiterated a Hold rating citing higher oncology-driven estimates but constrained upside, which may temper upside momentum despite pipeline wins. TipRanks: Hold rating
• Negative Sentiment: Bayer legal challenge over prostate cancer product claims — Bayer has initiated legal action related to prostate cancer product claims, introducing litigation risk and potential costs or reputational impact that investors dislike. Yahoo: Legal challenge mention

Analyst Ratings Changes

Several research firms recently weighed in on JNJ. Morgan Stanley set a $262.00 target price on shares of Johnson & Johnson and gave the company an “overweight” rating in a research note on Wednesday, January 28th. Sanford C. Bernstein increased their price target on shares of Johnson & Johnson from $208.00 to $225.00 and gave the company a “market perform” rating in a research note on Friday, January 23rd. Bank of America reissued a “neutral” rating on shares of Johnson & Johnson in a research report on Monday. Leerink Partners upped their target price on shares of Johnson & Johnson from $201.00 to $232.00 and gave the company a “market perform” rating in a report on Thursday, January 22nd. Finally, Wells Fargo & Company raised their target price on shares of Johnson & Johnson from $230.00 to $240.00 and gave the company an “overweight” rating in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $232.70.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.